Market cap of KOSPI pharmaceutical index dropped by KRW 2.4481 trillion in January

[Newsmp] In the first month of 2023, the weakness in the pharmaceutical index continued.

According to the Korea Exchange, the KOSPI pharmaceutical index fell 340.28p or 2.47% from 13,793.83 at the end of December to 13,453,55 at the end of January.

The stock prices of 28 stocks, more than half of the 47 stocks, declined from the end of December, and the market capitalization of 26 stocks decreased.

The market cap of Samsung Biologics, which accounts for more than half of the market capitalization of the KOSPI pharmaceutical index, plummeted by nearly KRW 2 trillion.

Gene One Life Science had the highest growth of 18.9%, and Yungjin Pharm. recorded double-digit growth of 10.3%.

Along with them, shares of a total of eight stocks rose more than 5%, including ORIENTBIO 9.6%, Daewoong 8.8%, Boryung Pharmaceutical and Dong-A ST 6.3%, Bukwang Pharmaceutical 6.1%, and JW Pharmaceutical 5.6%.

Chong Kun Dang Holdings, Samsung Pharmaceutical, SK Bioscience, PharmGen Science, Ilsung Pharmaceutical, Dong Wha Pharm, Korea United Pharm., Kwang Dong Pharmaceutical, Hankdok, and Celltrion saw their share prices edge up from the end of December.

On the other hand, Aprogen Pharmaceuticals stock plunged more than 20% by 27.2%, Kyongbo Pharmaceutical by 23.0%, and Il Dong Holdings by 20.2%, while Hana Pharm also recorded double-digit declines by 14.2%, Hanmi Pharmaceutical by 13.9%, and Daewon Pharmaceutical by 10.3%.

Moreover, the stock prices of 13 drug makers, Reyon Pharmaceutical, Il Dong Pharmaceutical, Kukje Pharma, Yuhan Corporation, Pharmicell, HanAll Biopharma, and Samjin Pharmaceutical, fell by more than 5%.

Daewoong Pharmaceutical also slid from the end of December, including Dongsung Pharmaceutical, Samsung Biologics, Samil Pharmaceutical, Jeil Pharmaceutical, Il-Yang Pharmaceutical, Myungmoon Pharmaceutical, Shin Poong Pharmaceutical, JW Life Science, BioNote, Hyundai Pharmaceutical, Chong Kun Dang Pharmaceutical, Whanin Pharmaceutical, Green Cross, and Yuyu Pharma

Accordingly, the market capitalization of 47 stocks in the KOSPI pharmaceutical index also decreased by KRW 2.4481 trillion from 114.119 trillion at the end of December to KRW 111.5638 trillion at the end of January.

Samsung Biologics’ market capitalization shrank by KRW 1.9929 trillion over the past month, Hanmi Pharmaceutical’s by KRW 448.6 billion and Yuhan Corporation’s by KRW 180.6 billion.

Unlikely, Celltrion expanded by KRW 154.9 billion, SK Bioscience by KRW 115.2 billion, Gene One Life Science by KRW 105.0 billion, and Daewoong by KRW 104.7 billion, increasing market capitalization by more than KRW 100 billion.

Although the stock prices of Aprogen Pharmaceuticals and Chong Kun Dang Pharmaceutical declined slightly, their market caps rose by KRW 13.9 billion and KRW 41.4 billion.

As of 31 Jan., Samsung Biologics had the largest market cap of KRW 56.441 trillion, followed by Celltrion of KRW 22.7541 trillion and SK Bioscience of KRW 5.7588 trillion.

Yuhan Corporation came next with KRW 4.0082 trillion, Hanmi Pharmaceutical with KRW 3.2222 trillion, Daewoong Pharmaceutical KRW 1.7646 trillion, Green Cross KRW 1.5064 trillion, Daewoong with KRW 1.2878 trillion, Shin Poong Pharmaceutical with KRW 1.1021 trillion, and Chong Kun Dang Pharmaceutical with KRW 1.0256 trillion, a total of 10 stocks surpassing KRW 1 trillion.